On Wednesday, Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS), lost -16.22% to $0.07, hitting its lowest level.
Aeterna Zentaris shares took a bounce to $.085 on Friday from its low of $.08, after a fall from $.21 on July 21. With the impending phase III results expected in early October the following due diligence may provide insight for current and potential shareholders.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -1.63% to $58.03, during its last trading session.
Bristol-Myers Squibb Company and Pfizer Inc. declared that the first patient has been enrolled into the Phase 4 clinical trial, AUGUSTUS. This two-by-two factorial, randomized controlled trial will evaluate the safety of Eliquis as compared to warfarin or other vitamin K antagonists (VKA) in patients with nonvalvular atrial fibrillation (NVAF) and a recent acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), also known as a stent. In addition, patients will also be randomized to aspirin or placebo. All patients will receive a P2Y12 inhibitor (such as clopidogrel) in combination with either Eliquis or a VKA. Eliquis is approved to reduce the risk of stroke and systemic embolism in patients with NVAF.
AUGUSTUS is anticipated to enroll 4,600 eligible patients from 30 countries. The two-by-two factorial design permits for the testing of two hypotheses in the study population. First, it will evaluate whether or not Eliquis is noninferior to a VKA on the combined outcome of major bleeding and clinically relevant non-major (CRNM) bleeding when studied in an open-label manner. Second, in a double-blind manner, it will evaluate whether or not the addition of aspirin to an anticoagulant and P2Y12 inhibitor results in significantly more major and CRNM bleeding in the study population.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, Joy Global, Inc. (NYSE:JOY), ended its last trade with -1.69% loss, and closed at $18.62.
Joy Global’s price target was lowered to $25 from $48 at BMO Capital this morning. Its rating remain unchanged at “outperform.”
The firm made this change following Joy’s fiscal third quarter 2015 results, which were declared late last week. Service orders were at $537 million, down 16% year over year, which surprised BMO.
Adjusted earnings for third quarter 2015 were 54 cents per share, down from 80 cents per share in the same quarter last year. This missed BMO’s estimate of 60 cents per share.
Joy Global Inc. manufactures and services mining equipment for the extraction of coal, copper, iron ore, oil sands, gold, and other minerals. It operates in two segments, Underground Mining Machinery and Surface Mining Equipment.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
